Clinical Trials Logo

Respiratory Distress Syndrome, Newborn clinical trials

View clinical trials related to Respiratory Distress Syndrome, Newborn.

Filter by:

NCT ID: NCT03846960 Not yet recruiting - Clinical trials for Respiratory Distress Syndrome

Surfactant Administration Via Thin Catheter Using a Specially Adapted Video Laryngoscope

Start date: February 2019
Phase: N/A
Study type: Interventional

In this study the investigators intend to assess the feasibility of surfactant administration via a thin catheter using a specially adapted video laryngoscope, with a groove designed to allow insertion of an endovascular catheter without the use of other instruments in the oral cavity (forceps ect.). The laryngoscope is of Peak Medic Ltd, Netania, Israel.

NCT ID: NCT03844893 Not yet recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Macrophage Programing in Acute Lung Injury

Start date: March 2019
Study type: Observational

The histologic hallmarks of lung inflammation and in the extreme, acute respiratory distress syndrome (ARDS), include intense accumulation of inflammatory cells in the airspaces and interstitium, injury to alveolar epithelial and endothelial cells, loss of epithelial-capillary integrity and accumulation of edema fluid in the interstitium and airspaces. Accordingly, for alveolar repair to occur inflammation must be halted, debris and inflammatory cells removed, injured tissue cells replaced, and capillary barrier function re-established. Macrophages are key players in all of these. Here the investigators hypothesize that resident alveolar macrophages and recruited macrophages serve completely different functions, acting independently (i.e. division of labor) yet cooperatively (synergism).

NCT ID: NCT03842462 Not yet recruiting - Preterm Infant Clinical Trials

NHFOV vs NIPPV vs nCPAP in Preterm Infants With Respiratory Distress Syndrome

Start date: May 17, 2019
Phase: N/A
Study type: Interventional

This will be a prospective, multi-center, three-arms,parallel, randomized, controlled trial with a superiority design,conducted in China. The investigators conduct this multi-centre, randomized, controlled trial to test the hypothesis that NHFOV is more effective than nCPAP or NIPPV in the treatment of respiratory distress syndrome (RDS) in infants with a gestational age of less than 30 weeks or a birth weight of less than 1500g when used as a primary noninvasive ventilation (NIV) mode.

NCT ID: NCT03828630 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Lung Ultrasound to Detect Pulmonary Complications in Critically Ill Parturients

Start date: July 8, 2018
Study type: Observational

This study aims at describing the frequency, timing and type of pulmonary complications detected with lung ultrasound in critically-ill parturients in admitted to a high-dependency unit in Freetown, Sierra Leone.

NCT ID: NCT03827863 Not yet recruiting - Clinical trials for ARDS (Acute Respiratory Distress Syndrome)

Acute CorPulmonale and ARDS Circulation Protection China Study China (ACPC)

Start date: April 1, 2019
Study type: Observational

The investigators established a national cohort of Chinese ARDS with Acute CorPulmonale to enable prospective observational studies. The goals are the following. First, morbidity and mortality rate of ARDS with ACP in the ICU across Chinese mainland. Second, forming the diagnostic ultrasound strategy of ARDS-ACP, namely TRIP procedures. And predictive value of diagnostic strategy for ACP or prognosis of ACP were calculated. Third, comparison of ventilator parameters for ACP and non-ACP or survivor and non-survisors, which reaveald that of inappropriate mechanical ventilation on circulation and prognosis. Screening for risk factors of ARDS with ACP.

NCT ID: NCT03825835 Not yet recruiting - Premature Infant Clinical Trials

30% or 60% Oxygen at Birth to Improve Neurodevelopmental Outcomes in Very Low Birthweight Infants

Start date: October 1, 2019
Phase: N/A
Study type: Interventional

Preterm birth, or birth before 37 weeks' gestation, is increasingly common, occurring in 8% of pregnancies in Canada. Preterm birth is associated with many health complications, particularly when the birth happens before 29 weeks' gestation. At this gestational age, the lungs are not fully developed and it is not uncommon for infants to have problems breathing at the time of birth. One complication that can arise is when an infant stops breathing and needs to be resuscitated. When preterm babies need to be resuscitated doctors must take special care because of the small infant size and the immaturity of the brain and lungs. Oxygen is used to resuscitate babies who need it, but unfortunately there is disagreement about the best oxygen concentration to use. Oxygen concentration is important because both too much and too little oxygen can cause brain injury. This research aims to fill this knowledge gap by participating in an international clinical trial to compare the effects of resuscitating babies less than 29 weeks' gestational age with either a low oxygen concentration or a high oxygen concentration. The oxygen concentrations have been selected using the best available knowledge. This will be a cluster randomized trial where each participating hospital will be randomized to either 30 or 60% oxygen for the recruitment of 30infants, and afterwards randomized to the other group for the recruitment of another 30 infants. After the trial, the investigator will determine whether the babies resuscitated with low oxygen or those resuscitated with high oxygen have better survival and long-term health outcomes. This research fills a critical knowledge gap in the care of extremely preterm babies and will impact their survival both here in Canada and internationally.

NCT ID: NCT03818854 Not yet recruiting - Clinical trials for Respiratory Distress Syndrome, Adult

Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome

Start date: July 1, 2019
Phase: Phase 2
Study type: Interventional

This is a Phase 2b, randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) infusion in patients with Acute Respiratory Distress Syndrome (ARDS). This study is the extension of the Phase 1 pilot study (NCT01775774) and Phase 2a study (NCT02097641).

NCT ID: NCT03808402 Recruiting - Clinical trials for Bronchopulmonary Dysplasia

The Effect of Surfactant Dose on Outcomes in Preterm Infants With RDS

Start date: October 26, 2018
Study type: Observational

A prospective observational study using de-identified data from the Neonatal Network Research Database (NNRD) supplemented by additional information on dose, method of surfactant administration and dosing frequency to assess whether the dose and method of administration of surfactant given to preterm infants with respiratory distress syndrome (RDS) affects neonatal outcomes.

NCT ID: NCT03807804 Active, not recruiting - Clinical trials for Respiratory Distress Syndrome, Adult

Efficacy and Safety Study of HLCM051(MultiStem®) for Pneumonic Acute Respiratory Distress Syndrome

Start date: January 1, 2019
Phase: Phase 2
Study type: Interventional

The primary object of this clinical study is to investigate the efficacy of HLCM051 in patients with ARDS caused by pneumonitis.

NCT ID: NCT03799874 Not yet recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Safety and Efficacy Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)

Start date: January 2019
Phase: Phase 2
Study type: Interventional

This study will be a multi-center, prospective, randomized, partially double-blind, placebo-controlled Phase II clinical trial of inhaled CO (iCO) for the treatment of ARDS. The trial will be conducted at 5 tertiary care medical centers including Weill Cornell Medicine/NewYork-Presbyterian Hospital, Brigham and Women's Hospital (BWH), Massachusetts General Hospital (MGH), Duke University Hospital, and the Durham Veterans Administration Medical Center. The purpose of this study is to evaluate the safety, tolerability, and efficacy of inhaled carbon monoxide (iCO) for the treatment of ARDS and to examine the biologic readouts of low dose iCO therapy in patients with ARDS